

# Characterization of Healthcare-Associated and Community-Associated *Clostridioides difficile* Infections among Adults, Canada, 2015–2019

Tim Du,<sup>1</sup> Kelly B. Choi,<sup>1</sup> Anada Silva, George R. Golding, Linda Pelude, Romeo Hizon, Ghada N. Al-Rawahi, James Brooks, Blanda Chow, Jun C. Collet, Jeannette L. Comeau, Ian Davis, Gerald A. Evans, Charles Frenette, Guanghong Han, Jennie Johnstone, Pamela Kibsey, Kevin C. Katz, Joanne M. Langley, Bonita E. Lee, Yves Longtin, Dominik Mertz, Jessica Minion, Michelle Science, Jocelyn A. Srigley, Paula Stagg, Kathryn N. Suh, Nisha Thampi, Alice Wong, Susy S. Hota

We investigated epidemiologic and molecular characteristics of healthcare-associated (HA) and community-associated (CA) *Clostridioides difficile* infection (CDI) among adult patients in Canadian Nosocomial Infection Surveillance Program hospitals during 2015–2019. The study encompassed 18,455 CDI cases, 13,735 (74.4%) HA and 4,720 (25.6%) CA. During 2015–2019, HA CDI rates decreased by 23.8%, whereas CA decreased by 18.8%. HA CDI was significantly associated with increased 30-day all-cause mortality as compared with CA CDI ( $p < 0.01$ ).

Of 2,506 isolates analyzed, the most common ribotypes (RTs) were RT027, RT106, RT014, and RT020. RT027 was more often associated with CDI-attributable death than was non-RT027, regardless of acquisition type. Overall resistance *C. difficile* rates were similar for all drugs tested except moxifloxacin. Adult HA and CA CDI rates have declined, coinciding with changes in prevalence of RT027 and RT106. Infection prevention and control and continued national surveillance are integral to clarifying CDI epidemiology, investigation, and control.

*Clostridioides difficile* is a major cause of infectious nosocomial diarrhea in high-income countries (1). Disease severity ranges from asymptomatic colonization to fulminant colitis, sometimes leading to colectomy and death (2). Healthcare costs attributed to *C. difficile* infection (CDI) are estimated to be \$4.8 billion in

the United States and €3 billion in Europe (3). A study in Canada estimated 38,000 annual CDI cases and conservative estimated costs of CDN \$280 million resulting from extended hospital stays and rehospitalization (4).

The epidemiology of *C. difficile* has evolved markedly in the past decade (1). Whereas CDI was once

Author affiliations: National Microbiology Laboratory, Winnipeg, Manitoba, Canada (T. Du, G.R. Golding, R. Hizon); Public Health Agency of Canada, Ottawa, Ontario, Canada (K.B. Choi, A. Silva, L. Pelude, J. Brooks); British Columbia Children's Hospital, Vancouver, British Columbia, Canada (G.N. Al-Rawahi); Alberta Health Services, Calgary, Alberta, Canada (B. Chow); BC Children's & Women's Hospitals, Vancouver (J.C. Collet, J.A. Srigley); Dalhousie University, Halifax, Nova Scotia, Canada (J.L. Comeau); Queen Elizabeth II Health Sciences Centre, Halifax (I. Davis); Kingston Health Sciences Centre, Kingston, Ontario, Canada (G.A. Evans); McGill University Health Centre, Montréal, Quebec, Canada (C. Frenette); Provincial Infection Control Network, Vancouver (G. Han); Sinai Health, Toronto, Ontario, Canada (J. Johnstone); Royal Jubilee Hospital, Victoria, British Columbia, Canada (P. Kibsey); North York General

Hospital, Toronto (K.C. Katz); IWK Health Centre, Halifax (J.M. Langley); Stollery Children's Hospital, Edmonton, Alberta, Canada (B.E. Lee); Jewish General Hospital, Montréal (Y. Longtin); Hamilton Health Sciences, Hamilton, Ontario, Canada (D. Mertz); Regina General Hospital, Regina, Saskatchewan, Canada (J. Minion); The Hospital for Sick Children, Toronto (M. Science); Western Memorial Regional Hospital, Corner Brook, Newfoundland and Labrador, Canada (P. Stagg); The Ottawa Hospital, Ottawa (K.N. Suh); Children's Hospital of Eastern Ontario, Ottawa (N. Thampi); Royal University Hospital, Saskatoon, Saskatchewan, Canada (A. Wong); University Health Network, Toronto (S.S. Hota)

DOI: <https://doi.org/10.3201/eid2806.212262>

<sup>1</sup>These authors contributed equally to this article.

believed to be mostly healthcare-associated (HA), increased evidence points to transmission in community settings (5,6). An estimated 40% of patients with community-associated (CA) CDI require hospitalization; 20% experience treatment failure, and 28% have recurrent CDI episodes (7).

Several international studies have reported changes in molecular and epidemiologic characteristics of CDI in healthcare and community settings (8–13); we investigated changes in adult CA CDI epidemiology in Canada. The Canadian Nosocomial Infection Surveillance Program (CNISP) collects standardized epidemiologic and laboratory-linked data from sentinel hospitals across Canada, currently representing 30% of all acute care beds. We previously reported a decrease in HA CDI rates during 2009–2015, associated with a reduction in ribotype (RT) 027 (1). Here, we describe findings of a multicenter study evaluating incidence, patient characteristics, outcomes, RT prevalence, and antimicrobial resistance rates for HA and CA CDI identified during 2015–2019 in hospitals participating in CNISP. We also assessed associations between predominant RTs and all-cause and CDI-attributable deaths.

## Methods

### Case Definition

We used previously described case definitions for primary CDI (14) (Appendix, <https://wwnc.cdc.gov/EID/article/28/6/21-2262-App1.pdf>). A case of HA CDI was defined on the basis of laboratory confirmation of CDI and a compatible clinical syndrome developing  $\geq 72$  hours after admission, or  $< 72$  hours after admission if the patient had a previous admission to the hospital and was discharged within the previous 4 weeks. CA CDI was defined as clinical manifestation of CDI symptoms  $\leq 72$  hours before admission with no history of hospitalization or healthcare exposure, including outpatient healthcare exposures, within the previous 12 weeks.

Severe outcomes were defined as CDI-attributable admission to an intensive care unit (ICU), colectomy, or death  $\leq 30$  days after admission. All deaths were reviewed by an infectious disease physician or medical microbiologist by using clinical judgement to determine whether deaths were CDI-attributable.

### Data Sources and Collection

CNISP has conducted prospective surveillance for HA CDI in hospitalized patients in Canada since 2007, and CA CDI surveillance was added in 2015. By 2019, CNISP included a network of 76 acute care hospitals across 10 provinces and 1 territory

(Appendix Table 1). We analyzed data collected during 2015–2019 from adult and mixed (adult and pediatric) hospitals. The Canadian Network for Public Health Intelligence collected and verified clinical and laboratory surveillance data to ensure accuracy, as previously described (14).

### Bacterial Culture and Molecular Characterization

We performed *C. difficile* isolation by using an ethanol shock treatment method, then selected for *C. difficile* on *Clostridium difficile* Moxalactam Norfloxacin agar (Oxoid, <https://www.oxoid.com>), as previously described (15,16). We prepared DNA for PCR analysis and ribotyping by using InstaGene Matrix (Bio-Rad, <https://www.bio-rad.com>), as previously described (17). We performed multiplex PCR targeting toxin A (*tcdA*), toxin B (*tcdB*), binary toxin (*cdtB*), negative regulator of toxin production (*tcdC*), and triose phosphate isomerase (*tpi*) housekeeping gene, as previously described (15,18,19), with slight modifications. We substituted an in-house A3B primer (5'-ACCATCAATCTC-GAAAAGTCCAC-3') for the *tcd*-R reverse primer for detecting *tcdA* (420 bp amplicon) and the detection of *tcdA* deletion variants (147 bp amplicon).

### PCR Ribotyping

We performed capillary gel electrophoresis-based ribotyping targeting the 16S–23S intergenic spacer region, as previously described (17). We assigned RTs by comparing query profiles to those of a reference set of RTs used in a previous multicenter international study (17).

### Antimicrobial Susceptibility Testing

We used Etest strips (bioMérieux, <https://www.biomerieux.com>) to perform susceptibility testing for metronidazole, clindamycin, vancomycin, rifampin, moxifloxacin, and tigecycline, as previously described (16,20). We interpreted antimicrobial resistance in accordance with Clinical and Laboratory Standards Institute guidelines (20).

### Statistical Analysis

We calculated HA CDI incidence rates as number of cases per 10,000 patient-days and CA CDI incidence rates as number of cases per 1,000 patient admissions. We used the Cochran-Armitage test for categorical variables and the Mann-Kendall test for continuous variables to assess statistically significant trends over time for patient characteristics and outcome results. To compare characteristics of patients with HA CDI versus CA CDI, we used the  $\chi^2$  test for categorical variables and the Student *t* test or Wilcoxon rank sum test for continuous variables.

We used multivariable logistic regression to model the association between RTs and outcomes (i.e., 30-day all-cause and 30-day CDI-attributable mortality) and adjusted for a priori-selected confounders of age, sex, severe CDI cases (albumin level <30 g/L, leukocyte count  $\geq 15 \times 10^9/L$ , or both), and CDI case types (i.e., HA vs. CA CDI). We used 2-tailed statistical tests and considered  $p \leq 0.05$  statistically significant. We performed all analyses in SAS version 9.4 (SAS Institute Inc., <https://www.sas.com>).

## Results


Our analysis included a total of 18,455 adult inpatient cases of primary CDI from participating hospitals during 2015–2019. HA CDI accounted for 74.4% ( $n = 13,735$ ) of cases and CA for 25.6% ( $n = 4,720$ ). The number of hospitals participating in HA CDI surveillance each year ranged from 58–64, and 46–54 hospitals participated in CA CDI surveillance (Appendix Table 1). We also completed a sensitivity analysis to restrict hospitals that conducted both HA and CA CDI surveillance but observed no statistically significant differences in results (data not shown).

During 2015–2019, HA CDI rates decreased by 23.8%, from 4.74 to 3.61 cases/10,000 patient-days ( $p < 0.02$ ), and CA CDI rates decreased by 18.8%, from 1.33 to 1.08 cases/1,000 admissions ( $p < 0.33$ ) (Figure 1). Regionally, HA CDI rates decreased significantly in the central ( $p < 0.02$ ) and western ( $p < 0.02$ ) regions of Canada, but rates fluctuated in the eastern region ( $p = 0.62$ ), peaking at 4.06 cases/10,000 patient-days in 2019. Despite a decline, CA CDI infection rates remained highest in the central region, at 1.53 cases/1,000 admissions in 2019. Of the 64 hospitals for which data were available for adult CDI surveillance, 58 (91%) reported data for the entire 5-year period of surveillance. After restricting our analyses to these 58 hospitals, interpretation of our results did not change. Incidence rates for HA CDI decreased by 22.8%, CA CDI incidence decreased by 18.0%, and rates were consistent with those reported and generated with data from 64 hospitals.

We aggregated patient characteristics and outcomes by case type (Table 1). Compared with HA CDI patients, CA CDI patients were younger (median age 67.0 vs. 70.0 years;  $p < 0.01$ ), and more CA CDI patients were female (56.0% vs. 49.1% male;  $p < 0.01$ ).

## Clinical Manifestations

Of the 18,455 cases, 3,084 had clinical and outcome data available; these data are collected during a 2-month targeted surveillance period (March–April) each year. Overall, 10.4% (316/3,033) of patients with



**Figure 1.** National and regional healthcare-associated (A) and community-associated (B) *Clostridioides difficile* infection rates among adults, Canada, 2015–2019. Western region is British Columbia, Alberta, Saskatchewan, and Manitoba; Central region is Ontario and Quebec; Eastern region is Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland and Labrador.

CDI died, and 2.9% (86/3,019) of deaths were CDI-attributable (Table 1). Of 316 deaths among patients with CDI, 27.2% (86/316) were CDI-attributable. Patients with HA CDI had significantly higher 30-day all-cause mortality than patients with CA CDI (11.4% vs. 7.3%;  $p < 0.01$ ). Of 3,073 patients with CDI, 207 (6.8%) required ICU admission, 27.5% (57/207) of whom were admitted because of CDI complications, and 1.9% (57/3,073) all patients with CDI were admitted to the ICU because of CDI complications. We observed no statistically significant differences in ICU admission by acquisition type.

During 2015–2019, ICU admission data were available for 2,340 HA CDI patients (433–507 patients annually). ICU admissions decreased significantly among HA CDI cases, from 9.1% (46/507) in 2015 to 5.9% (26/442) in 2019 ( $p < 0.02$ ). We saw no statistically significant trends for age, sex, or 30-day outcomes for all-cause or CDI-attributable deaths (Appendix Table 2).

## Ribotyping Analysis

Of the 18,455 cases, a total of 3,189 stool samples were received for *C. difficile* isolation at the National

**Table 1.** Clinical and molecular characteristics of healthcare-associated and community-associated *Clostridioides difficile* infection among adults, Canada, 2015–2019\*

Characteristics	Healthcare-associated	Community-associated	All cases	p value
Routine surveillance, no. (%)†	13,735 (74.4)	4,720 (25.6)	18,455	
Patient characteristics				
Age, y				
Mean (SD)	68.3 (16.9)	64.4 (18.4)	67.3 (17.4)	<0.001
Median (IQR)	70.0 (59.0–81.0)	67.0 (54.0–79.0)	70.0 (58.0–80.0)	<0.001
Sex, no. (%)				
F	6,747 (49.1)	2,645 (56.0)	9,392 (50.9)	<0.001
M	6,988 (50.9)	2,075 (44.0)	9,063 (49.1)	
Targeted surveillance, no. (%)‡	2,350 (76.2)	734 (23.8)	3,084	
Clinical results and outcomes				
Median (IQR) leukocyte count, × 10 <sup>9</sup> cells/L	10.9 (23.0–33.0)	10.6 (6.9–15.7)	10.8 (7.1–16.0)	NS
Median (IQR) albumin, g/L	26.0 (22.0–31.0)	28.0 (23.0–33.0)	27.0 (22.0–32.0)	0.0232
FMT, no. positive/no. tested (%)§	11/3,645 (0.3)	4/1,557 (0.3)	15/5,202 (0.3)	NS
Colectomy, no. positive/no. tested (%)	30/2,255 (1.3)	15/725 (2.1)	45/2,980 (1.5)	NS
Loop ileostomy, no. positive/no. tested (%)	2/798 (0.3)	3/270 (1.1)	5/1,068 (0.5)	NS
ICU admission, no. (%)	n = 2,340	n = 733	n = 3,073	
All cause	156 (6.7)	51 (7.0)	207 (6.8)	NS
Due to complications of CDI	46 (2.0)	11 (1.5)	57 (1.9)	NS
30-d mortality, no. (%)	n = 2,302	n = 731		
Death, all causes	263 (11.4)	53 (7.3)	316/3,033 (10.4)	0.0001
Death, attributable to CDI	69 (3.0)	17 (2.3)	86/3,019 (2.9)	NS

\*Missing or unknown values were excluded from the analysis.  $\chi^2$  test was used to assess statistical significance for categorical variables; Student *t* test, or the Wilcoxon rank sum test was used for continuous variables. CDI, *Clostridioides difficile* infection; FMT, fecal microbiota transplantation; ICU, intensive care unit; IQR, interquartile range; NS, not significant.

†Patient characteristics data collected year-round.

‡Clinical results and outcome data are collected during a 2-month targeted surveillance period (March–April) each year except FMT where the data were collected year-round.


§FMT data collection started in 2018.

Microbiology Laboratory (Winnipeg, Manitoba, Canada), and 2,506 samples met inclusion criteria. Of samples tested, 1,887 (75.3%) were HA CDI and 619 (24.7%) were CA CDI. We performed capillary gel electrophoresis ribotyping and antimicrobial susceptibility testing to further characterize isolates.

Among 1,887 HA CDI isolates characterized during the study period, we noted 170 unique PCR RTs (Figure 2). The most common RTs among HA CDI were RT027 (16.0%), RT106 (11.5%), RT014 (8.6%),

RT020 (6.4%), and RT002 (5.7%). The 15 most prevalent RTs accounted for 69.6% of isolates tested (Appendix Table 3). The prevalence of RT027 in HA CDI cases decreased from 24.6% in 2015 to 9.4% in 2019 ( $p < 0.01$ ), but the incidence of RT106 increased from 7.3% in 2015 to 18.1% in 2019 ( $p < 0.01$ ).

Of 619 CA CDI isolates, we noted 115 unique RTs, of which RT106 (12.3%), RT020 (8.4%), RT014 (8.1%), RT027 (7.9%), and RT056 (5.0%) were the most prevalent. For CA CDI, the 15 most prevalent RTs



**Figure 2.** Prevalence of *Clostridioides difficile* ribotypes detected each year from healthcare-associated (A) and community-associated (B) infections among adults, Canada, 2015–2019.

accounted for 66.1% of isolates tested (Appendix Table 3). As for HA CDI, we noted a decrease in prevalence of RT027, from 14.8% in 2015 to 2.8% in 2019 ( $p < 0.01$ ) and RT106 increased from 6.5% in 2015 to 17.6% in 2019 ( $p < 0.01$ ). Despite a steady decline in prevalence over the study period, RT027 remained the most commonly isolated strain type with an overall combined prevalence of 14.0% (351/2,506 isolates).

RT078 and RT126 are livestock-associated strains that correlate with increased virulence and disease severity and have been identified in human CDIs. RT078 and RT126 prevalence among HA CDI cases averaged 2.4% (range 2.0%–3.2%), but for CA CDI, RT078 and RT126 prevalence averaged 1.9% (range 0.8%–3.2%) (Appendix Table 4).

### All-Cause and CDI-Attributable Deaths

Among patients with reported 30-day all-cause mortality ( $n = 316$ ) and 30-day CDI-attributable mortality ( $n = 86$ ), most were HA CDI: 80.2% (263/316) of all-cause and 83.7% (69/86) of CDI-attributable deaths. In addition, more deaths occurred among female patients, who made up 55.4% (175/316) of all-cause and 57.0% of CDI-attributable (49/86) deaths, and more patients  $\geq 65$  years of age, who comprised 79.8% (252/316) of all-cause and 83.7% of CDI-attributable deaths (72/86).

After multivariable analysis, patient characteristics significantly associated with 30-day all-cause mortality and 30-day CDI-attributable mortality were age  $\geq 65$  years and severe CDI (Table 2). The adjusted odds ratio of 30-day all-cause mortality among patients with HA CDI was 1.83 (95% CI 1.23–2.72) times more than for patients with CA CDI ( $p < 0.01$ ). Similarly, the adjusted odds ratio of 30-day CDI-attributable mortality was 1.25 (95% CI 0.67–2.35) times higher among HA CDI than CA CDI, but this difference was not statistically significant.

### Analysis of RT027 and RT106 Outcomes

Among 2,320 case-patients with available data on 30-day all-cause mortality, 316 (13.6%) were reported to have died (Appendix Table 5). Of 235 deaths among patients with associated ribotyping data, 44 (18.7%) deaths were associated with RT027 and 30 (12.8%) deaths with RT106. Among RT027 cases, a significantly higher proportion of 30-day all-cause mortality was associated with HA CDI cases than with CA CDI cases ( $p = 0.01$ ). We saw no statistically significant difference in 30-day all-cause mortality between HA and CA CDI cases associated with RT106. We also saw no statistically significant difference in CDI-attributable deaths when stratified by HA and CA CDI cases for RT027 and RT106.

**Table 2.** Univariable and multivariable analysis of 30-day all-cause and *Clostridioides difficile*-attributable mortality, Canada, 2015–2019\*

Characteristics	Univariable analysis		Multivariable analysis	
	Odds ratio (95% CI)	p value	Adjusted odds ratio (95% CI)	p value
All-cause mortality				
Sex				
M	Referent		Referent	
F	1.15 (0.91–1.45)	0.2484	1.26 (0.93–1.70)	NS
Age group, y				
<65	Referent		Referent	
$\geq 65$	<b>2.66 (2.00–3.53)</b>	<b>&lt;0.0001</b>	<b>3.63 (2.45–5.39)</b>	<b>&lt;0.0001</b>
Severe CDI†	<b>2.53 (1.90–3.36)</b>	<b>&lt;0.0001</b>	<b>2.66 (1.90–3.73)</b>	<b>&lt;0.0001</b>
CDI case type				
Community-associated	Referent		Referent	
Healthcare-associated	<b>1.65 (1.21–2.24)</b>	<b>0.0014</b>	<b>1.83 (1.23–2.72)</b>	<b>0.0028</b>
RT027 vs. non-RT027	<b>1.48 (1.04–2.10)</b>	<b>0.0289</b>	1.10 (0.74–1.63)	NS
RT106 vs. non-RT106	1.09 (0.73–1.63)	0.6804	NA	
CDI-attributable mortality				
Sex				
M	Referent		Referent	
F	1.22 (0.79–1.87)	0.3776	1.33 (0.81–1.19)	NS
Age group, y				
<65	Referent		Referent	
$\geq 65$	<b>3.28 (1.84–5.85)</b>	<b>&lt;0.0001</b>	<b>3.44 (1.73–6.82)</b>	<b>0.0004</b>
Severe CDI†	<b>2.40 (1.45–4.0)</b>	<b>0.0006</b>	<b>2.25 (1.28–3.94)</b>	<b>0.0050</b>
CDI case type				
Community-associated	Referent		Referent	
Healthcare-associated	1.29 (0.76–2.22)	0.3476	1.25 (0.67–2.35)	NS
RT027 vs. non-RT027	<b>3.17 (1.89–5.29)</b>	<b>&lt;0.0001</b>	<b>2.85 (1.64–5.00)</b>	<b>0.0002</b>
RT106 vs. non-RT106	0.95 (0.45–2.00)	0.8830	NA	

\*Bold text indicates statistical significance. CDI, *Clostridioides difficile* infection; NA, not applicable; NS, not significant; RT, ribotype.

†Severe CDI defined as albumin level  $< 30$  g/L, leukocyte count  $\geq 15 \times 10^9$  cells/L, or both.

Of 162 cases with severe outcomes for which ribotype analysis was available in the HA CDI population, 33 (11.7%) were associated with RT027 and 10 (4.8%) were associated with RT106 ( $p < 0.01$ ). We also noted a small number of severe outcomes associated with RT027 ( $n = 2$ ) and RT106 ( $n = 3$ ) in CA CDI cases; however, we noted no statistically significant differences between HA and CA CDI.

Multivariate analysis found RT027 was significantly associated with 30-day CDI-attributable mortality (adjusted odds ratio [aOR] 2.85, 95% CI 1.64–5.00) compared with non-RT027 cases ( $p < 0.01$ ). However, the association of RT027 with the outcome of 30-day all-cause mortality did not remain statistically significant compared with non-RT027 cases when controlling for other factors within the multivariate model (aOR 1.10, 95% CI 0.74–1.63). When compared with non-RT106 cases, RT106 was not significantly associated with either 30-day all-cause ( $p = 0.68$ ) or CDI attributable ( $p = 0.88$ ) mortality in the univariate model.

### Antimicrobial Susceptibility

We conducted antimicrobial resistance testing for HA and CA CDI isolates collected during 2015–2019 (Figure 3; Appendix Tables 6, 7). During the study years, HA CDI resistance was 21.7% to moxifloxacin, 31.0% to clindamycin, and 1.9% to rifampin and CA CDI resistance was 12.4% to moxifloxacin, 33.6% to clindamycin, and 1.5% to rifampin. Of note, HA CDI resistance to moxifloxacin decreased from 34.3% in 2015 to 13.5% in 2019. Similarly, CA CDI resistance to moxifloxacin declined from 18.7% in 2015 to 11.1% in 2019. Resistance to clindamycin was more variable in both study populations, overall resistance was 32.3% (range 19%–54%) (Figure 3).

RT027 accounted for 60.2% (293/487) of identified moxifloxacin-resistant isolates. Of note, 83.5% (293/351) of all RT027 isolates examined were moxifloxacin-resistant, of which 97.3% (285/293) had MICs  $\geq 32$   $\mu\text{g}/\text{mL}$ . Among RT027 isolates, resistance was higher in HA CDI (85.4%; 258/302) than CA CDI (71.4%; 35/49) cases. In contrast, RT106, the second most prevalent strain type (11.7%), accounted for 6.0% of all moxifloxacin-resistant isolates. Fluoroquinolone resistance in RT106 isolates was much lower (9.9%; 29/293), and resistance values were similar for both HA (10.6%) and CA settings (7.9%).

RT027 strains also were more likely to be associated with resistance to  $\geq 1$  antimicrobial drug. Of 172 isolates resistant to both moxifloxacin and clindamycin, 79 (45.9%) were RT027. Of 22 isolates found to be resistant to moxifloxacin, clindamycin, and rifampin,


68.2% (15/22) were RT027; of these, 12 were from HA CDI cases and 3 were from CA CDI cases. No other RT strain exhibited resistance to  $\geq 1$  drug with a prevalence  $> 5\%$ .

We did not observe resistance for metronidazole, vancomycin, or tigecycline for any study year in either HA or CA CDI populations. One adult patient with HA CDI in 2019 had intermediate susceptibility to vancomycin (MIC 6  $\mu\text{g}/\text{mL}$ ) but sensitivity to all other drugs tested.

### Discussion

Using 5 years of CDI surveillance data from acute care hospitals across Canada, we observed a decline in rates of HA and CA CDI that coincided with a marked change in the prevalence of predominant circulating ribotypes. The epidemiologic and molecular characterization of HA and CA CDI revealed differences in patient characteristics and select clinical outcomes, with associations to predominant ribotypes.

The decline in CDI rates in Canada follows a parallel trend observed globally, despite rates being higher in North America (10,21). We previously reported HA CDI rates ranging from 2.1 to 6.6 cases/10,000 inpatient days during 2011–2016 but showing a decreasing trend over time (13). We noted an increase in CA CDI rates in that study, but in this study, we found that rates of CA CDI have decreased since 2015. Although the precise reasons for decreased CDI incidence in Canada are unclear, enhanced infection control and antimicrobial stewardship measures combined with improved surveillance methods might have contributed to the overall decline (22). Furthermore, patients with mild to moderate CA CDI might not be admitted to or tested in a hospital, resulting in underestimation of the true burden of CA CDI.



**Figure 3.** Antimicrobial resistance rates for HA and CA *Clostridioides difficile* infections among adults, Canada, 2015–2019. CA, community-associated; HA, healthcare-associated.

Although molecular surveillance of CDI in Canada revealed a dynamic and heterogeneous RT population, the predominant circulating types were RT027, RT106, RT020, and RT014. Similar to findings in this study, RT027 has been reported to be decreasing in prevalence in North America, the United Kingdom, and elsewhere; however, RT027 remains a major cause of CDI (1,23–26). In Canada, the dramatic decrease in RT027 prevalence in HA CDI has continued since its initial reporting (1). Declining trends observed among HA (–15.2%) and CA (–12.0%) CDI during 2015–2019 in Canada are also consistent with trends in the United States, where HA CDI rates declined from 21% to 15% and CA CDI declined from 17% to 6% during 2012–2017 (25).

Although RT027 prevalence in Canada decreased during 2015–2019, RT106 greatly increased during the same period, from 7.3% to 18.1% in healthcare settings and from 6.5% to 17.6% in community settings. Identified in the United Kingdom in 1999 (27), RT106 is now found worldwide and is one of the most predominant strains in the United States (28). Studies indicate that RT106 has enhanced spore-producing and biofilm formation capabilities that enable greater persistence in the environment and hospital settings, possibly leading to increased infection rates (28,29). In addition, studies report that patients infected with RT106 are more likely to experience multiple episodes of relapse (28,30).

*C. difficile* RT078 and RT126, which have demonstrated epidemic potential in other countries (31–33), appear to be uncommon in patients hospitalized with CDI in Canada. Our surveillance shows a small increase in RT078 and RT126 prevalence since a previous report showed rates of 2.4% in HA and 1.9% CA CDI populations (14).

Similar to previous findings, our study showed that CA CDI patients were more likely to be younger and female (10,34–36). In addition, this study found that HA CDI is associated with an increased risk for 30-day all-cause mortality compared with CA CDI; however, this association did not remain significant for CDI-attributable deaths. Hospitalized patients with CDI possibly are exposed to other risks and complications during their hospital stay or have underlying conditions that increase their risk for all-cause death. Our findings agree with previously published studies assessing all-cause and CDI-attributable death (34,37).

We further analyzed the effects of RT027 and RT106, the 2 most prevalent *C. difficile* strains, on all-cause and CDI-attributable death. We previously showed a significant association between RT027 and attributable mortality (1). In this study, we concluded that RT027 is a significant predictor of CDI-attributable death even after adjusting for case type (HA or

CA CDI). We noted no association between RT106 and all-cause and CDI-attributable deaths.

We found that *C. difficile* antimicrobial resistance is less common in Canada than in the United States or globally (38). Stratified by case type, HA and CA CDI isolates revealed no significant difference in resistance, except for moxifloxacin resistance, which was 21.7% for HA and 12.4% for CA CDI, consistent with previously reported findings (30). In addition, diverse RT populations observed in both HA and CA CDI might be predictive of lower resistance rates observed because RT heterogeneity has been shown to be inversely correlated with antimicrobial resistance as measured by cumulative resistance scores (12,39).

Our study's first limitation is that hospital participation in HA and CA CDI surveillance varied by year and might have affected trends over time. Furthermore, hospitals self-select whether to participate in both HA and CA CDI surveillance, which might have influenced the comparison of HA and CA CDI patients. To mitigate this limitation, we conducted a sensitivity analysis restricted to hospitals that conducted both HA and CA CDI surveillance. Second, although CDI diagnostic testing methods were collected throughout the study period, data completeness was not consistent from year to year, limiting the inferences we could make regarding the effect of CDI diagnostic testing methods on adult CDI rates over time. Third, for CA CDI surveillance, our study captured data from patients admitted to a CNISP hospital and requiring medical intervention for CDI symptoms or other underlying conditions. The features and outcomes of these patients might not be relevant to patients with CA CDI who do not require hospital care. Finally, although a qualified physician determined the cause of death in patients with CDI, attribution of death is difficult and could be subjective.

In conclusion, rates of HA and CA CDI in Canada declined during 2015–2019, coinciding with a decrease in prevalence of RT027 and increased prevalence of RT106. HA CDI was associated with higher rates of all-cause death than was CA CDI, and RT027 was a major predictor of CDI-attributable death, irrespective of location of acquisition. We noted major decreases in antimicrobial resistance to moxifloxacin in both HA and CA CDI populations, concordant with an overall decrease in prevalence of RT027. Despite declining rates, CDI continues to be a major health burden in Canada. To ensure continued success in combatting this global health threat, robust national surveillance and infection prevention and control programs are integral to clarifying CDI epidemiology, investigation, and control.

## Acknowledgment

We gratefully acknowledge the physicians, epidemiologists, infection control practitioners, and laboratory staff at each participating hospital for their contributions. We thank the staff at the Public Health Agency of Canada, especially Joelle Cayen, Sean Ahmed, and Jennifer Campbell.

This work was supported by the Public Health Agency of Canada.

Canadian Nosocomial Infection Surveillance Program hospitals provided expertise in the development of protocols in addition to epidemiological data and laboratory isolates. National Microbiology Laboratory staff and epidemiologists from Public Health Agency of Canada were responsible for the conception, analysis, interpretation, drafting, and revision of the paper.

## About the Authors

Dr. Du is a biologist with the Public Health Agency of Canada in Winnipeg, Manitoba, Canada. His primary research interests include the epidemiology of *Clostridioides difficile* in addition to antimicrobial resistance in hospital acquired infections. Dr. Choi is an epidemiologist with Canadian Nosocomial Infection Surveillance Program, Public Health Agency of Canada, Ottawa, Ontario, Canada. Her primary research interest is antimicrobial-resistant infections, including *C. difficile* infection and surgical site infections.

## References

- Katz KC, Golding GR, Choi KB, Pelude L, Amaratunga KR, Taljaard M, et al.; Canadian Nosocomial Infection Surveillance Program. The evolving epidemiology of *Clostridium difficile* infection in Canadian hospitals during a postepidemic period (2009–2015) [cited 2021 May 7]. *CMAJ*. 2018;190:E758–65. <https://doi.org/10.1503/cmaj.180013>
- Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, et al.; Canadian Nosocomial Infection Surveillance Program. Health care-associated *Clostridium difficile* infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. *Clin Infect Dis*. 2009;48:568–76. <https://doi.org/10.1086/596703>
- Bouza E. Consequences of *Clostridium difficile* infection: understanding the healthcare burden. *Clin Microbiol Infect*. 2012;18:5–12. <https://doi.org/10.1111/1469-0691.12064>
- Levy AR, Szabo SM, Lozano-Ortega G, Lloyd-Smith E, Leung V, Lawrence R, et al. Incidence and costs of *Clostridium difficile* infections in Canada. *Open Forum Infect Dis*. 2015;2:ofv076. <https://doi.org/10.1093/ofid/ofv076>
- Zanichelli V, Garenc C, Villeneuve J, Moisan D, Frenette C, Loo V, et al.; Québec *C. difficile* Infection Surveillance Program (SPIN-CD). Increased community-associated *Clostridioides difficile* infections in Quebec, Canada, 2008–2015. *Emerg Infect Dis*. 2020;26:1291–4. <https://doi.org/10.3201/eid2606.190233>
- Gupta A, Khanna S. Community-acquired *Clostridium difficile* infection: an increasing public health threat. *Infect Drug Resist*. 2014;7:63–72.
- Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM. Outcomes in community-acquired *Clostridium difficile* infection. *Aliment Pharmacol Ther*. 2012;35:613–8. <https://doi.org/10.1111/j.1365-2036.2011.04984.x>
- Lee J-H, Lee Y, Lee K, Riley TV, Kim H. The changes of PCR ribotype and antimicrobial resistance of *Clostridium difficile* in a tertiary care hospital over 10 years. *J Med Microbiol*. 2014;63:819–23. <https://doi.org/10.1099/jmm.0.072082-0>
- Thornton CS, Rubin JE, Greninger AL, Peirano G, Chiu CY, Pillai DR. Epidemiological and genomic characterization of community-acquired *Clostridium difficile* infections. *BMC Infect Dis*. 2018;18:443. <https://doi.org/10.1186/s12879-018-3337-9>
- Kotila SM, Mentula S, Ollgren J, Virolainen-Julkunen A, Lyytikäinen O. Community- and healthcare-associated *Clostridium difficile* infections, Finland, 2008–2013. *Emerg Infect Dis*. 2016;22:1747–53. <https://doi.org/10.3201/eid2210.151492>
- Snydman DR, McDermott LA, Jenkins SG, Goldstein EJC, Patel R, Forbes BA, et al. Epidemiologic trends in *Clostridioides difficile* isolate ribotypes in United States from 2011 to 2016. *Anaerobe*. 2020;63:102185. <https://doi.org/10.1016/j.anaerobe.2020.102185>
- Freeman J, Vernon J, Pilling S, Morris K, Nicolson S, Shearman S, et al.; Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent *Clostridium difficile* Ribotypes' Study Group. Five-year pan-European, longitudinal surveillance of *Clostridium difficile* ribotype prevalence and antimicrobial resistance: the extended ClosER study. *Eur J Clin Microbiol Infect Dis*. 2020;39:169–77. <https://doi.org/10.1007/s10096-019-03708-7>
- Xia Y, Tunis MC, Frenette C, Katz K, Amaratunga K, Rhodenizer Rose S, et al. Epidemiology of *Clostridioides difficile* infection in Canada: a six-year review to support vaccine decision-making. *Can Commun Dis Rep*. 2019;45:191–211. <https://doi.org/10.14745/ccdr.v45i78a04>
- Canadian Nosocomial Infection Surveillance Program. Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018. *Canada Commun Dis Rep*. 2020;46:99–112. <https://doi.org/10.14745/ccdr.v46i05a01>
- Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, et al. Health care-associated *Clostridium difficile* infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. *Clin Infect Dis*. 2010;50:194–201. <https://doi.org/10.1086/649213>
- Lynch T, Chong P, Zhang J, Hizon R, Du T, Graham MR, et al.; Canadian Nosocomial Infection Surveillance Program (CNISP). Characterization of a stable, metronidazole-resistant *Clostridium difficile* clinical isolate. *PLoS One*. 2013;8:e53757. <https://doi.org/10.1371/journal.pone.0053757>
- Fawley WN, Knetsch CW, MacCannell DR, Harmanus C, Du T, Mulvey MR, et al. Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for *Clostridium difficile*. *PLoS One*. 2015;10:e0118150. <https://doi.org/10.1371/journal.pone.0118150>
- Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, et al. Multiplex PCR targeting *tpi* (triose phosphate isomerase), *tcdA* (Toxin A), and *tcdB* (Toxin B) genes for toxigenic culture of *Clostridium difficile*. *J Clin Microbiol*. 2004;42:5710–4. <https://doi.org/10.1128/JCM.42.12.5710-5714.2004>
- Spigaglia P, Mastrantonio P. Comparative analysis of *Clostridium difficile* clinical isolates belonging to different



- genetic lineages and time periods. *J Med Microbiol.* 2004;53:1129–36. <https://doi.org/10.1099/jmm.0.45682-0>
20. Clinical and Laboratory Standards Institute. *Methods for antimicrobial susceptibility testing of anaerobic bacteria*, 9th edition. CLSI standard M11. Wayne (PA): The Institute; 2018.
  21. Ho J, Wong SH, Doddangoudar VC, Boost MV, Tse G, Ip M. Regional differences in temporal incidence of *Clostridium difficile* infection: a systematic review and meta-analysis. *Am J Infect Control.* 2020;48:89–94. <https://doi.org/10.1016/j.ajic.2019.07.005>
  22. Pereira JA, McGeer A, Tomovici A, Selmani A, Chit A. Incidence and economic burden of *Clostridioides difficile* infection in Ontario: a retrospective population-based study. *CMAJ Open.* 2020;8:E16–25. <https://doi.org/10.9778/cmajo.20190018>
  23. Jassem AN, Prystajecy N, Marra F, Kibsey P, Tan K, Umlandt P, et al. Characterization of *Clostridium difficile* strains in British Columbia, Canada: a shift from NAP1 majority (2008) to novel strain types (2013) in one region. *Can J Infect Dis Med Microbiol.* 2016;2016:8207418. <https://doi.org/10.1155/2016/8207418>
  24. Karlowsky JA, Zhanel GG, Hammond GW, Rubinstein E, Wylie J, Du T, et al. Multidrug-resistant North American pulsotype 2 *Clostridium difficile* was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006–2007. *J Med Microbiol.* 2012;61:693–700. <https://doi.org/10.1099/jmm.0.041053-0>
  25. Centers for Disease Control and Prevention. 2018 Annual report for the Emerging Infections Program for *Clostridioides difficile* infection [cited 2021 Jun 25]. <https://www.cdc.gov/hai/eip/Annual-CDI-Report-2017.html>.
  26. Public Health England. *Clostridium difficile* Ribotyping Network (CDRN) for England and Northern Ireland, 2015–2018. London: Public Health England; 2019.
  27. Stubbs SLJ, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of *Clostridium difficile* and construction of a library consisting of 116 different PCR ribotypes. *J Clin Microbiol.* 1999;37:461–3. <https://doi.org/10.1128/JCM.37.2.461-463.1999>
  28. Carlson TJ, Blasingame D, Gonzales-Luna AJ, Alnezary F, Garey KW. *Clostridioides difficile* ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. *Anaerobe.* 2020;62:102142. <https://doi.org/10.1016/j.anaerobe.2019.102142>
  29. Roxas BAP, Roxas JL, Claus-Walker R, Harishankar A, Mansoor A, Anwar F, et al. Phylogenomic analysis of *Clostridioides difficile* ribotype 106 strains reveals novel genetic islands and emergent phenotypes. *Sci Rep.* 2020;10:22135. <https://doi.org/10.1038/s41598-020-79123-2>
  30. Suárez-Bode L, Barrón R, Pérez JL, Mena A. Increasing prevalence of the epidemic ribotype 106 in healthcare facility-associated and community-associated *Clostridioides difficile* infection. *Anaerobe.* 2019;55:124–9. <https://doi.org/10.1016/j.anaerobe.2018.12.002>
  31. Keessen EC, Harmanus C, Dohmen W, Lipman LJA, Kuijper EJ. *Clostridium difficile* infection associated with pig farms. *Emerg Infect Dis.* 2013;19:1032–4. <https://doi.org/10.3201/eid1906.121645>
  32. Mulvey MR, Boyd DA, Gravel D, Hutchinson J, Kelly S, McGeer A, et al. Hypervirulent *Clostridium difficile* strains in hospitalized patients, Canada. *Emerg Infect Dis.* 2010;16:678–81. <https://doi.org/10.3201/eid1604.091152>
  33. Knetsch CW, Kumar N, Forster SC, Connor TR, Browne HP, Harmanus C, et al. Zoonotic transfer of *Clostridium difficile* harboring antimicrobial resistance between farm animals and humans. *J Clin Microbiol.* 2018;56:e01384-17. <https://doi.org/10.1128/JCM.01384-17>
  34. Kwon SS, Gim JL, Kim MS, Kim H, Choi JY, Yong D, et al. Clinical and molecular characteristics of community-acquired *Clostridium difficile* infections in comparison with those of hospital-acquired *C. difficile*. *Anaerobe.* 2017;48:42–6. <https://doi.org/10.1016/j.anaerobe.2017.06.014>
  35. Tan XQ, Verrall AJ, Jureen R, Riley TV, Collins DA, Lin RT, et al. The emergence of community-onset *Clostridium difficile* infection in a tertiary hospital in Singapore: a cause for concern. *Int J Antimicrob Agents.* 2014;43:47–51. <https://doi.org/10.1016/j.ijantimicag.2013.09.011>
  36. Fellmeth G, Yarlagadda S, Iyer S. Epidemiology of community-onset *Clostridium difficile* infection in a community in the South of England. *J Infect Public Health.* 2010;3:118–23. <https://doi.org/10.1016/j.jiph.2010.07.002>
  37. Crobach MJT, Notermans DW, Harmanus C, Sanders IMJG, De Greeff SC, Kuijper EJ. Community-onset *Clostridioides difficile* infection in hospitalized patients in the Netherlands. *Open Forum Infect Dis.* 2019;6:ofz501. <https://doi.org/10.1093/ofid/ofz501>
  38. Peng Z, Jin D, Kim HB, Stratton CW, Wu B, Tang YW, et al. Update on antimicrobial resistance in *Clostridium difficile*: resistance mechanisms and antimicrobial susceptibility testing. *J Clin Microbiol.* 2017;55:1998–2008. <https://doi.org/10.1128/JCM.02250-16>
  39. Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, et al.; Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent *Clostridium difficile* Ribotypes' Study Group. Pan-European longitudinal surveillance of antibiotic resistance among prevalent *Clostridium difficile* ribotypes. *Clin Microbiol Infect.* 2015;21:248.e9–16. <https://doi.org/10.1016/j.cmi.2014.09.017>

---

Address for correspondence: George Golding, Surveillance, Reference and Science Directorate of the National Microbiology Laboratory Branch, One Health Division, Antimicrobial Resistance and Nosocomial Infections, National Microbiology Laboratory, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada; email: [george.golding@phac-aspc.gc.ca](mailto:george.golding@phac-aspc.gc.ca)

# Characterization of Healthcare-Associated and Community-Associated *Clostridioides difficile* Infections among Adults, Canada, 2015–2019

## Appendix

### Surveillance Case Definitions and Eligibility Criteria

#### *Clostridioides difficile* Infection (CDI)

A “primary” episode of CDI is defined as either the first episode of CDI ever experienced by the patient or a new episode of CDI, which occurs greater than eight weeks after the diagnosis of a previous episode in the same patient.

A patient is identified as having CDI if:

- The patient has diarrhea or fever, abdominal pain and/or ileus AND a laboratory confirmation of a positive toxin assay or positive polymerase chain reaction (PCR) for *C. difficile* (without reasonable evidence of another cause of diarrhea)

OR

- The patient has a diagnosis of pseudomembranes on sigmoidoscopy or colonoscopy (or after colectomy) or histological/pathological diagnosis of CDI

OR

- The patient is diagnosed with toxic megacolon (in adult patients only)

Diarrhea is defined as one of the following:

- More watery/unformed stools in a 36-h period
- or more watery/ unformed stools in a 24-h period and this is new or unusual for the patient (in adult patients only)

Exclusion:

- Any patients younger than one year
- Any pediatric patients (aged one year to younger than 18 y) with alternate cause of diarrhea found (i.e., rotavirus, norovirus, enema or medication, etc.) are excluded even if *C. difficile* diagnostic test result is positive

#### CDI Case Classification

Once a patient has been identified with CDI, the infection will be classified further based on the following criteria and the best clinical judgment of the healthcare and/or infection prevention and control practitioner.

Healthcare-associated (acquired in your facility) CDI case definition

- Related to the current hospitalization
  - The patient’s CDI symptoms occur in your healthcare facility three or more days (or  $\geq 72$  h) after admission
- Related to a previous hospitalization
  - The patient’s CDI symptoms occur less than three days after the current admission (or less than 72 h) AND the patient had been previously hospitalized at your healthcare facility and discharged within the previous four weeks
- Related to a previous healthcare exposure at your facility
  - The patient’s CDI symptoms occur less than three days after the current admission (or less than 72 h) AND the patient had a previous healthcare exposure at your facility within the previous four weeks

Healthcare-associated (acquired in any other healthcare facility) CDI case definition

- Related to a previous hospitalization at any other healthcare facility
  - The patient’s CDI symptoms occur less than three days after the current admission (or less than 72 h) AND the patient is known to have been previously hospitalized at any other healthcare facility and discharged/transferred within the previous four weeks
- Related to a previous healthcare exposure at any other healthcare facility
  - The patient’s CDI symptoms occur less than three days after the current admission (or  $<72$  h) AND the patient is known to have a previous healthcare exposure at any other healthcare facility within the previous four weeks

**Community-Associated CDI Case Definition**

The patient’s CDI symptoms occur less than three days (or less than 72 h) after admission, with no history of hospitalization or any other healthcare exposure within the previous 12 weeks.

**Appendix Table 1.** Number of Canadian Nosocomial Infection Surveillance Program adult and mixed (adult and pediatric) hospitals in each region included in a study of *Clostridioides difficile* infection among adults, Canada, 2015–2019\*

Region	2015	2016	2017	2018	2019
<b>Healthcare-associated</b>					
Western	22	22	22	22	22
Central	22	22	23	23	26
Eastern	14	15	15	15	15
Northern	0	0	0	0	1
All	58	59	60	60	64
<b>Community-associated</b>					
Western	12	12	12	12	12
Central	20	21	23	23	26
Eastern	14	15	15	15	15
Northern	0	0	0	0	1
All	46	48	50	50	54

\*Western region includes British Columbia, Alberta, Saskatchewan, and Manitoba; Central includes Ontario and Quebec; Eastern includes Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland and Labrador; and Northern includes Nunavut. The Northern region was included in national rates but not displayed in regional stratification due to zero reported cases of *Clostridioides difficile*.

**Appendix Table 2.** Clinical characteristics and outcome trends of patients with *Clostridioides difficile* infection over time, Canada, 2015–2019\*

Characteristics	2015	2016	2017	2018	2019	p value
<b>Healthcare-associated <i>C. difficile</i> infection</b>						
Sex, no. (%)†						
M	1,487 (50.1)	1,452 (50.4)	1,454 (51.7)	1,326 (49.9)	1,268 (52.5)	NS
F	1,479 (49.9)	1,430 (49.6)	1,360 (48.3)	1,329 (50.1)	1,149 (47.5)	NS
Median age, y (IQR)†	71 (59–82)	70 (58–81)	71 (59–81)	70 (59–81)	71 (59–81)	NS
ICU admission, no./total (%)‡						
All cause	46/507 (9.1)	33/466 (7.1)	29/492 (5.9)	22/433 (5.1)	26/442 (5.9)	<b>0.0188</b>
Complication from CDI	13/507 (2.6)	8/466 (1.7)	11/492 (2.2)	5/433 (1.2)	9/442 (2.0)	NS
30-day outcome death, no./total (%)‡						
All cause death	68/504 (13.5)	51/442 (11.5)	49/486 (10.1)	49/429 (11.4)	46/441 (10.4)	NS
Attributable to CDI	21/504 (4.2)	14/442 (3.2)	16/485 (3.3)	6/424 (1.4)	12/438 (2.7)	NS
<b>Community-associated <i>C. difficile</i> infection</b>						
Sex, no. (%)†						
M	426 (44.0)	384 (42.7)	453 (45.9)	445 (44.6)	367 (42.3)	NS
F	543 (56.0)	516 (57.3)	533 (54.1)	553 (55.4)	500 (57.7)	NS
Median age, y (IQR)†	67 (54–79)	66 (54–79)	66 (54–78)	67 (54–78)	67 (55–79)	NS
ICU admission, no./total (%)‡						
All cause	16/164 (9.8)	11/146 (7.5)	4/141 (2.8)	11/145 (7.6)	9/137 (6.6)	NS
Complication from CDI	3/164 (1.8)	2/146 (1.4)	3/141 (2.1)	1/145 (0.7)	2/137 (1.5)	NS
30-day outcome death, no./total (%)‡						
All cause death	11/164 (6.7)	12/146 (8.2)	7/141 (5.0)	7/144 (4.9)	16/136 (11.8)	NS
Attributable to CDI	4/164 (2.4)	4/146 (2.7)	1/140 (0.7)	3/143 (2.1)	5/133 (3.8)	NS

\*Missing or unknown values were excluded from the analysis. The Cochran–Armitage test was used for categorical variables and the Mann–Kendall test for continuous variables to assess significant trends over time. Bold text indicates statistical significance. CDI, *Clostridioides difficile* infection; ICU, intensive care unit; NS, not significant.

†Patient demographic characteristics data (age and sex) collected year-round.

‡ICU admission and mortality data are collected during a 2-month targeted surveillance period (March–April) each year.

**Appendix Table 3.** Top 15 most prevalent healthcare-associated and community-associated *Clostridioides difficile* ribotypes among adults, Canada, 2015–2019

Ribotypes	2015	2016	2017	2018	2019
<b>Healthcare-associated, %</b>					
027	24.59	15.30	18.72	9.92	9.36
106	7.33	13.31	8.87	11.29	18.13
014	8.04	8.22	7.39	8.82	11.11
020	6.38	6.80	5.91	7.16	5.85
002	7.33	5.10	4.43	6.06	5.56
056	3.07	4.53	3.94	4.68	3.80
015	1.89	2.83	1.97	4.13	3.80
076	3.31	1.70	3.94	2.48	0.88
057	2.13	2.27	2.96	3.03	0.88
012	1.18	1.70	0.99	3.58	2.63
103	0.95	2.55	0.74	2.48	2.34
072	3.31	1.98	1.97	0.28	0.29
078	2.13	1.13	2.22	0.83	1.46
629	1.18	1.42	0.99	1.65	2.05
153	1.18	2.27	1.72	1.10	0.58
Other	26.00	28.90	33.25	32.51	31.29
<b>Community-associated, %</b>					
106	6.45	9.48	15.32	14.73	17.59
020	8.39	9.48	8.11	8.53	7.41
014	5.16	7.76	9.91	10.08	8.33
027	14.84	10.34	6.31	3.10	2.78
056	4.52	5.17	2.70	8.53	3.70
002	5.81	5.17	5.41	3.88	4.63
015	2.58	1.72	5.41	3.88	9.26
012	3.23	2.59	4.50	4.65	3.70
629	3.23	0.00	0.90	1.55	2.78
153	0.65	2.59	3.60	1.55	0.93
019	1.29	2.59	1.80	2.33	0.00
328	3.23	0.86	0.90	2.33	0.00
078	2.58	2.59	0.00	0.78	0.93
076	0.65	1.72	1.80	1.55	1.85
054	0.00	1.72	0.90	1.55	3.70
Other	37.42	36.21	32.43	31.01	32.41

**Appendix Table 4.** Prevalence of livestock-associated *Clostridioides difficile* ribotypes 078/126, Canada, 2015–2019

Ribotype 078/126	2015	2016	2017	2018	2019	2015–2019
Healthcare-associated, no. (%)	10 (2.4)	7 (2.0)	13 (3.2)	9 (2.2)	7 (2.1)	2.4
Community-associated, no. (%)	5 (3.2)	3 (2.6)	1 (0.9)	1 (0.8)	2 (1.9)	1.9

**Appendix Table 5.** Outcomes of ribotype 027 and ribotype 106 by healthcare-associated and community-associated *Clostridioides difficile* infection, 2015–2019, Canada\*

Ribotypes	All-cause death			<i>C. difficile</i> -attributable death			Severe outcomes†		
	HA	CA	p value	HA	CA	p value	HA	CA	p value
RT027	43/277 (15.5)	1/48 (2.1)	0.0102	22/275 (8.0)	1/48 (2.1)	0.2217	33/282 (11.7)	2/48 (4.2)	0.1348
RT106	26/204 (12.8)	4/73 (5.5)	0.1227	7/204 (3.4)	1/73 (1.4)	0.6853	10/210 (4.8)	3/74 (4.1)	1.0000

\*Values represent no. deaths/no. cases (%) unless otherwise noted. CA, community-associated; HA, healthcare-associated; RT, ribotype.

†Severe outcomes include CDI attributable ICU admission, colectomy and death combined.

**Appendix Table 6.** MIC<sub>50</sub> and MIC<sub>90</sub> of healthcare-associated and community-associated *Clostridioides difficile* infection, Canada, 2015–2019\*

Ant	Set	2015			2016			2017			2018			2019			Study period average		
		MIC <sub>50</sub>	MIC <sub>90</sub>	Range	MIC <sub>50</sub>	MIC <sub>90</sub>	Range	MIC <sub>50</sub>	MIC <sub>90</sub>	Range	MIC <sub>50</sub>	MIC <sub>90</sub>	Range	MIC <sub>50</sub>	MIC <sub>90</sub>	Range	MIC <sub>50</sub>	MIC <sub>90</sub>	Range
Mox	HA	1.5	>32	0.25 to >32	1.5	>32	0.38 to >32	1.5	>32	0.38 to >32	1.5	>32	0.50 to >32	1.5	>32	0.50 to >32	1.5	>32	0.25 to >32
	CA	1.5	>32	0.50 to >32	1.5	>32	0.38 to >32	1	3	0.38 to >32	1.5	2	0.50 to >32	1.5	32	0.75 to >32	1.5	>32	0.38 to >32
Cli	HA	3	>256	0.125 to >256	3	256	0.047 to 256	3	96	0.094 to >256	4	>256	0.25 to >256	4	>256	0.25 to >256	3	>256	0.047 to >256
	CA	3	>256	0.094 to >256	2	256	0.094–256	3	96	0.25 to >256	6	12	0.75 to >256	3	12	0.25 to >256	3	128	0.094 to >256
Rif	HA	0.002	0.003	<0.002 to >32	0.002	0.003	<0.002 to >32	0.002	0.003	<0.002 to >32	0.002	0.004	<0.002 to >32	0.002	0.003	<0.002 to >32	0.002	0.003	<0.002 to >32
	CA	0.002	0.003	<0.002 to >32	0.002	0.003	<0.002 to >32	<0.002	0.002	<0.002 to >32	0.002	0.004	<0.002 to >32	0.002	0.004	<0.002 to >32	0.002	0.003	<0.002 to >32
Van	HA	0.5	0.75	0.19–3	0.5	0.75	0.25–4	0.5	0.75	0.19–3	0.75	1	0.25–3	0.75	1	0.38–6	0.5	1	0.19–6
	CA	0.5	0.75	0.25–1.5	0.5	0.75	0.19–1.5	0.5	0.75	0.25–1.0	0.75	1	0.38–1.5	0.75	1	0.25–2	0.5	1	0.19–2
Met	HA	0.25	1	0.032 to 2	0.25	0.75	0.032 to 3	0.25	1	0.023 to 3	0.38	0.5	0.023 to 3	0.38	0.75	0.064 to 4	0.38	0.75	0.023–4
	CA	0.19	0.5	0.047–1.5	0.25	0.75	0.047–2.0	0.25	0.5	0.047–2.0	0.38	0.5	0.094–2.0	0.38	0.75	0.047–3.0	0.25	0.5	0.047–3
Tig	HA	0.064	0.125	<0.016–0.25	0.032	0.047	<0.016–0.094	0.032	0.047	<0.016–0.38	0.032	0.047	0.016–0.25	0.047	0.125	0.023–0.38	0.047	0.094	<0.016–0.38
	CA	0.064	0.125	<0.016–0.19	0.032	0.047	<0.016–0.38	0.032	0.047	0.016–0.094	0.047	0.047	0.016–0.094	0.047	0.125	0.016–0.5	0.047	0.094	<0.016–0.5

\*Values expressed as µg/mL. MIC<sub>50</sub>, MIC required to inhibit the growth of 50% of the isolates; MIC<sub>90</sub>, MIC required to inhibit the growth of 90% of the isolates. Ant, antimicrobial drug tested; CA, community-associated; Cli, clindamycin; HA, healthcare-associated; Met, metronidazole; Mox, moxifloxacin; Rif, rifampin; Set, setting; Tig, tigecycline; Van, vancomycin.

**Appendix Table 7.** Antimicrobial resistance interpretation healthcare-associated and community-associated *Clostridioides difficile* infection, Canada, 2015–2019\*

Ant	2015						2016						2017						2018						2019					
	HA, n = 423; CA, n = 155						HA, n = 353; CA, n = 116						HA, n = 406; CA, n = 111						HA, n = 363; CA, n = 129						HA, n = 342; CA, n = 108					
	Sus		Inter		Res		Sus		Inter		Res		Sus		Inter		Res		Sus		Inter		Res		Sus		Inter		Res	
No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Mox																														
HA	273	64.5	5	1.2	145	34.3	271	76.8	7	2.0	75	21.3	312	76.9	0	0	94	23.2	309	85.1	4	1.1	50	13.8	294	86.0	2	0.6	46	13.5
CA	126	81.3	0	0.0	29	18.7	97	83.6	4	3.5	15	12.9	99	89.2	1	0.9	11	9.9	117	90.7	2	1.6	10	7.8	93	86.1	3	2.8	12	11.1
Cli																														
HA	183	43.3	131	31.0	109	25.8	160	45.3	105	29.8	88	24.9	196	48.3	120	29.6	90	22.2	80	22.0	115	31.7	168	46.3	117	34.2	94	27.5	131	38.3
CA	75	48.4	25	22.6	45	29.0	59	50.9	27	23.3	30	25.9	50	45.1	40	36.0	21	18.9	24	18.6	35	27.1	70	54.3	42	38.9	24	22.2	42	38.9
Rif																														
HA	412	97.4	2	0.5	9	2.1	346	98.0	0	0	7	2.0	393	96.8	2	0.5	11	2.7	358	98.6	0	0	5	1.4	339	99.1	0	0	3	0.9
CA	152	98.1	0	0	3	1.9	115	99.1	0	0	1	0.9	110	99.1	0	0	1	0.9	127	98.5	0	0	2	1.6	106	98.2	0	0	2	1.9
Tig																														
HA	423	100	0	0	0	0	353	100	0	0	0	0	406	100	0	0	0	0	363	100	0	0	0	0	342	100	0	0	0	0
CA	155	100	0	0	0	0	116	100	0	0	0	0	111	100	0	0	0	0	129	100	0	0	0	0	108	100	0	0	0	0
Van																														
HA	423	100	0	0	0	0	353	100	0	0	0	0	406	100	0	0	0	0	363	100	0	0	0	0	341	99.7	1	0.3	0	0
CA	155	100	0	0	0	0	116	100	0	0	0	0	111	100	0	0	0	0	129	100	0	0	0	0	108	100	0	0	0	0
Met																														
HA	423	100	0	0	0	0	353	100	0	0	0	0	406	100	0	0	0	0	363	100	0	0	0	0	342	100	0	0	0	0
CA	155	100	0	0	0	0	116	100	0	0	0	0	111	100	0	0	0	0	129	100	0	0	0	0	108	100	0	0	0	0

\*Per Clinical and Laboratory Standards Institute guidelines; Methods for antimicrobial susceptibility testing of anaerobic bacteria, 9th edition. CLSI standard M11. Wayne, PA: The Institute; 2018. Ant, antimicrobial drug; CA, community-associated; HA, healthcare-associated; Inter, intermediate; Res, resistant; Sus, susceptible.

†Values expressed as µg/mL. Antimicrobial susceptibility interpretation: Moxifloxacin (Mox), susceptible ≤2, intermediate = 4, resistant ≥8; clindamycin (Cli), susceptible ≤2, intermediate = 4, resistant ≥8; rifampin (Rif), susceptible ≤1, intermediate = 2, resistant ≥4; vancomycin (Van), susceptible ≤4, intermediate = 8–16, resistant ≥32; metronidazole (Met), susceptible ≤8, intermediate = 16, resistant ≥32; tigecycline (Tig), susceptible ≤4, intermediate = 8, resistant ≥16.